Cernostics: Pittsburgh-based biotech firm Cernostics acquired for $30M

Pittsburgh-based biotech firm Cernostics will be acquired by Castle Biosciences Inc. in a deal worth at least $30 million. Castle (Nasdaq: CSTL) could pay up to $50 million more in cash and common stock depending on 2022 performance milestones. Cernostics Inc. uses artificial intelligence and spatial biology to analyze tissue biopsies through its platform TissueCypher Barrett's Esophagus Assay. The test Cernostics has developed detects the development of esophageal cancer and high-grade dysplasia...